$368 Million

Adaptive Biotechnologies Corp.

Follow-on Offering

Passive Bookrunner, July 2020

Adaptive is advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. The Company believes the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Adaptive’s immune medicine platform applies proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient. Adaptive captures these insights in its dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and uses them to develop and commercialize clinical products and services that are tailored to each individual patient. The Company has two commercial products and services and a robust pipeline of clinical products and services that are designed to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases.

More Like This

Aug 2020
$98 Million

Follow-on Offering

Bookrunner

View Details
Aug 2020
$838 Million
Horizon Therapeutics Logo

Follow-on Offering

Financial Advisor

View Details
Jul 2020
$58 Million

Follow-on Offering

Lead Left Bookrunner

View Details